SomaLogic

In this webinar, we’ll explore how integrating proteomics with systems biology sheds light on the complexities of AD pathology.

Introducing the SomaScan® 11K Assay – Pioneering proteomics. SomaLogic's high-plex, high throughput assay covers half the human proteome, empowering researchers to identify unique pathway and protein signatures. Explore the power of more.

Driving biomarker discovery is key as proteomics emerges as the next frontier in precision medicine.
In this webinar, you’ll hear how proteomics technology can enhance the identification of biomarkers for the accurate diagnosis of Crohn’s disease and ulcerative colitis, as well as the identification of biomarkers that predict response to TNF inhibitors and other biologics in patients with IBD.
This webinar will explore how reliable, non-invasive proteomic biomarkers are pivotal for personalized treatment and increasing our knowledge of biological pathways involved in disease. Our expert speaker will also present an assay platform that can measure 11,000 biologically relevant proteins in the search for biomarkers.

Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.

Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

While most protein assays excel in one or two areas, the SomaScan Assay is the first and only platform that can measure 7,000 proteins from a 55-µL sample – covering more biological pathways than any other proteomic assay.

The SomaScan Assay is an ideal high throughput platform for identifying proteins that may be involved in disease pathology, as it offers a highly sensitive method of quantifying proteins in different biologic fluids such as serum, plasma, urine and cerebrospinal fluid.

Developed for performance in human serum and plasma, the SomaScan Assay v4.1 can measure approximately 7,000 unique human protein analytes in small volumes of biological samples.

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.

In this Teach Me in 10 episode, Joe Gogain, director of clinical research and development at SomaLogic, will be discussing SomaSignal™ Tests.